NO992808L - Anvendelse av groenne porfyriner for fremstilling av et medikament for behandling av sekundµre katarakter - Google Patents

Anvendelse av groenne porfyriner for fremstilling av et medikament for behandling av sekundµre katarakter

Info

Publication number
NO992808L
NO992808L NO992808A NO992808A NO992808L NO 992808 L NO992808 L NO 992808L NO 992808 A NO992808 A NO 992808A NO 992808 A NO992808 A NO 992808A NO 992808 L NO992808 L NO 992808L
Authority
NO
Norway
Prior art keywords
drug
preparation
treatment
green porphyrins
secondary cataracts
Prior art date
Application number
NO992808A
Other languages
English (en)
Other versions
NO992808D0 (no
Inventor
Howard E Meadows
Danielle Wenkstern
David R Mallek
Nick Bussanich
Anna M Richter
Julia G Levy
Claude A A Hariton
Gustav Huber
Jack Rootman
Original Assignee
Qlt Phototherapeutics Inc
Univ British Columbia
Ciba Vision Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qlt Phototherapeutics Inc, Univ British Columbia, Ciba Vision Ag filed Critical Qlt Phototherapeutics Inc
Publication of NO992808D0 publication Critical patent/NO992808D0/no
Publication of NO992808L publication Critical patent/NO992808L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Fotodynamisk terapi for å forhindre sekundære katarakter foretas ved å benytte fotosensibilisatorer så som grønne porfyriner, som fotoaktive midler for å ødelegge gjenværende linseepitelceller.
NO992808A 1996-12-10 1999-06-09 Anvendelse av groenne porfyriner for fremstilling av et medikament for behandling av sekundµre katarakter NO992808L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/762,854 US6043237A (en) 1996-12-10 1996-12-10 Use of photodynamic therapy for prevention of secondary cataracts
PCT/CA1997/000949 WO1998025610A1 (en) 1996-12-10 1997-12-08 Use of green porphyrins for the manufacture of a medicament for the treatment of secondary cataracts

Publications (2)

Publication Number Publication Date
NO992808D0 NO992808D0 (no) 1999-06-09
NO992808L true NO992808L (no) 1999-08-09

Family

ID=25066203

Family Applications (1)

Application Number Title Priority Date Filing Date
NO992808A NO992808L (no) 1996-12-10 1999-06-09 Anvendelse av groenne porfyriner for fremstilling av et medikament for behandling av sekundµre katarakter

Country Status (15)

Country Link
US (2) US6043237A (no)
EP (1) EP0948329A1 (no)
JP (1) JP2001505885A (no)
KR (1) KR20000057510A (no)
CN (1) CN1246054A (no)
AR (1) AR010754A1 (no)
AU (1) AU737204B2 (no)
CA (1) CA2273010C (no)
HU (1) HUP0000576A3 (no)
IL (1) IL130404A0 (no)
NO (1) NO992808L (no)
NZ (1) NZ336196A (no)
PL (1) PL333951A1 (no)
WO (1) WO1998025610A1 (no)
ZA (1) ZA9711104B (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998013024A2 (en) * 1996-09-27 1998-04-02 Hyal Pharmaceutical Corporation Hyaluronic drug delivery system
WO2000012512A1 (en) 1998-08-28 2000-03-09 Destiny Pharma Limited Porphyrin derivatives, their use in photodynamic therapy and medical devices containing them
US6828439B1 (en) 1999-02-26 2004-12-07 Advanced Research And Technology Institute, Inc. Compounds, composition, and methods for photodynamic therapy
US7022843B1 (en) 1999-04-14 2006-04-04 The University Of British Columbia β,β′-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins
US6319273B1 (en) * 1999-12-16 2001-11-20 Light Sciences Corporation Illuminating device for treating eye disease
US6673067B1 (en) * 2000-01-31 2004-01-06 Gholam A. Peyman System and method for thermally and chemically treating cells at sites of interest in the body to impede cell proliferation
US7193706B2 (en) * 2000-08-02 2007-03-20 Arizona Board Of Regents, Acting On Behalf Of Arizona State University Computer interfaced scanning fluorescence lifetime microscope applied to directed evolution
US6514995B1 (en) 2000-09-25 2003-02-04 Advanced Research And Technology Institute, Inc. Enediyne compounds and methods related thereto
US7211603B1 (en) 2000-09-25 2007-05-01 Indiana University Research And Technology Corporation Enediyne compounds and methods related thereto
AU2895502A (en) * 2000-12-20 2002-07-01 Alcon Universal Ltd Solution for removing cataracts via liquefracture
US7753943B2 (en) * 2001-02-06 2010-07-13 Qlt Inc. Reduced fluence rate PDT
WO2002064163A2 (en) 2001-02-15 2002-08-22 Qlt Inc. Reduction or prevention of pdt related inflammation
US6838074B2 (en) 2001-08-08 2005-01-04 Bristol-Myers Squibb Company Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
EP1465590B1 (en) * 2001-11-02 2008-03-26 The Governors Of The University Of Alberta Micelle compositions containing pegylated phospholipids and a photosensitizer
US6723750B2 (en) 2002-03-15 2004-04-20 Allergan, Inc. Photodynamic therapy for pre-melanomas
DK1542997T3 (da) 2002-07-24 2012-06-25 Dermira Canada Inc Pyrazolylbenzothiazolderivater og deres anvendelse som terapeutiske midler
CA2500877A1 (en) * 2002-10-03 2004-04-15 Light Sciences Corporation Excitation of photoreactive compounds in eye tissue
DE602004023183D1 (de) * 2003-03-07 2009-10-29 Univ Texas Gegen antikörper gerichtete photodynamische therapie
US20050048109A1 (en) * 2003-08-26 2005-03-03 Ceramoptec Industries, Inc. Non-polar photosensitizer formulations for photodynamic therapy
US7252662B2 (en) * 2004-11-02 2007-08-07 Lenticular Research Group Llc Apparatus and processes for preventing or delaying one or more symptoms of presbyopia
US7468434B2 (en) * 2004-12-22 2008-12-23 The University Of Hong Kong Diazene-bridge crown ether lithium compounds and methods for their use
US9649224B2 (en) 2005-02-19 2017-05-16 Lenticular Research Group Llc Apparatus and processes for preventing or delaying onset or progression of age-related cataract
US9622911B2 (en) 2010-09-30 2017-04-18 Cxl Ophthalmics, Llc Ophthalmic treatment device, system, and method of use
US20130190737A1 (en) * 2012-01-10 2013-07-25 David Muller Application of energy in medical treatments
WO2013148895A1 (en) * 2012-03-29 2013-10-03 Cxl Ophthalmics, Llc Ocular cross-linking system and method for sealing corneal wounds
US9566301B2 (en) 2012-03-29 2017-02-14 Cxl Ophthalmics, Llc Compositions and methods for treating or preventing diseases associated with oxidative stress
EP2830627B1 (en) 2012-03-29 2024-05-01 Epion Therapeutics, Inc. Ocular treatment solutions, delivery devices and delivery augmentation methods
CN106620893B (zh) 2015-07-23 2021-07-30 爱博诺德(北京)医疗科技股份有限公司 用于眼部疾病光治疗的材料
US20230165718A1 (en) * 2021-11-29 2023-06-01 Alan Neil Glazier Methods, devices, and systems for treating lens protein aggregation diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202252A (en) * 1982-03-05 1993-04-13 Houston Biotechnology Inc. Monoclonal antibodies against lens epithelial cells and methods for preventing proliferation of remnant lens epithelial cells after extracapsular extraction
US4920143A (en) * 1987-04-23 1990-04-24 University Of British Columbia Hydro-monobenzoporphyrin wavelength-specific cytotoxic agents
US5095030A (en) * 1987-01-20 1992-03-10 University Of British Columbia Wavelength-specific cytotoxic agents
US5171749A (en) * 1987-01-20 1992-12-15 University Of British Columbia Wavelength-specific cytotoxic agents
US5283255A (en) * 1987-01-20 1994-02-01 The University Of British Columbia Wavelength-specific cytotoxic agents
US5401880A (en) * 1987-06-04 1995-03-28 Oculon Corporation Chemical prevention or reversal of cataract by phase separation inhibitors
US4966577A (en) * 1988-03-16 1990-10-30 Allergan, Inc. Prevention of lens-related tissue growth in the eye
US5273751A (en) * 1988-03-25 1993-12-28 Seymour Dubroff Composition for preventing clouding of paosterior capsule after extracapsular cataract eye surgery and method of performing cataract surgery
US5375611A (en) * 1993-01-26 1994-12-27 Pharmacia Ab Method for preventing secondary cataract
US5422362A (en) * 1993-07-29 1995-06-06 Quadra Logic Technologies, Inc. Method to inhibit restenosis
US5445637A (en) * 1993-12-06 1995-08-29 American Cyanamid Company Method and apparatus for preventing posterior capsular opacification
AU6813694A (en) * 1994-03-14 1995-10-03 Massachusetts Eye & Ear Infirmary Use of green porphyrins in ocular diagnosis and therapy
US5798349A (en) * 1994-03-14 1998-08-25 The General Hospital Corporation Use of green porphyrins to treat neovasculature in the eye

Also Published As

Publication number Publication date
NO992808D0 (no) 1999-06-09
JP2001505885A (ja) 2001-05-08
US6043237A (en) 2000-03-28
HUP0000576A2 (hu) 2000-11-28
EP0948329A1 (en) 1999-10-13
AU5220298A (en) 1998-07-03
AU737204B2 (en) 2001-08-09
WO1998025610A1 (en) 1998-06-18
PL333951A1 (en) 2000-01-31
US6248734B1 (en) 2001-06-19
KR20000057510A (ko) 2000-09-15
NZ336196A (en) 2000-10-27
CN1246054A (zh) 2000-03-01
ZA9711104B (en) 1998-07-10
IL130404A0 (en) 2000-06-01
HUP0000576A3 (en) 2002-09-30
CA2273010A1 (en) 1998-06-18
AR010754A1 (es) 2000-07-12
CA2273010C (en) 2007-03-13

Similar Documents

Publication Publication Date Title
NO992808L (no) Anvendelse av groenne porfyriner for fremstilling av et medikament for behandling av sekundµre katarakter
IT1333697B (no)
NO984163D0 (no) Forbedret syn ved fotodynamisk terapi av öyet
NO992524L (no) Konsenserte bicykliske pyrimidin-derivater
ES2160173T3 (es) Nuevo derivado de rodamina para la terapia fotodinamica de cancer y purgacion en vitro de leucemia.
RU2011138835A (ru) Применение производного рапамицина
EA200101156A1 (ru) ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НОВОГО ТИПА НА ОСНОВЕ ОБЛАДАЮЩИХ ХОЛИНЕРГИЧЕСКИМ ДЕЙСТВИЕМ СОЕДИНЕНИЙ И β-МИМЕТИКОВ
BR9607111A (pt) Uso de compostos de carbazol para o tratamento de deficiência cardíaca congestiva
PL319370A1 (en) Application of photodynamic therapy for selectively inactivating blood cells and treatment o diseases associated with immunological disturbances
HK1060974A1 (en) Sulfonated chlorines as photosensitizer
PT912184E (pt) Utilizacao de um derivado de k-252a para o tratamento de doencas do sietma nervoso central ou periferico e sobre-producao de citoquina
NO954878L (no) Pyrrolderivater
CA2335514A1 (en) Alkyl ether analogs of chlorins having an n-substituted imide ring
AR014964A1 (es) Derivados de indol, composiciones farmaceuticas que los contienen, agentes para reducir la presion intraocular, tratar glaucoma e hipertension ocular, usosen la fabricacion de composiciones farmaceuticas y procedimiento de fabricacion de dichas composiciones
WO2006041744A3 (en) Low energy pdt for ocular disease
MXPA02003522A (es) Derivados de rodamina para diagnostico fotodinamico y tratamiento.
CA2253207A1 (en) Growth inhibition and eradication of solid tumors using neuroendocrine resetting therapy and photodynamic therapy
CA2270558A1 (en) Treatment of autoimmune diseases by photochemotherapy
CA2279427A1 (en) Use of low dose photodynamic therapy for reducing the effects of inflammation
GB2360785A8 (en) 2-Aza-21-carbaporphyrins (N-confused porphyrins) with (hydroxy/alkoxy)phenyl meso-substituents for photodynamic therapy & the treatment of tumours
ATE297926T1 (de) Hexahydropyrazino(1'2':1,6)-pyrido(3,4-b)indole 1,4-dion-derivate zur behandlung von cardiovaskulären erkrankungen und erektionsstörungen
ES2083503T3 (es) Una imidazobenzodiazepina para el tratamiento de trastornos del sueño.
AU2002237239A1 (en) Use of 5-aminolevulinic acid for the prophylaxis of restenosis
UY25977A1 (es) 2-fenil-1- [4-(2-aminoetoxi)-bencil]- indoles como agentes estrogénicos
UY24769A1 (es) Derivados de vinilpirrolidinon-cefalosporina

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application